Temporal trends in cardiovascular burden among patients with prostate cancer receiving androgen deprivation therapy: a population-based cohort study

[31] Addolorato G(2014)ABCDE steps to prevent heart disease in breast cancer survivors Circulation. 130 e157-undefined

[32] Ammirati E(2016)Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer Circulation. 133 537-undefined

[33] Baddour LM(2020)Management of cardiac toxicity induced by chemotherapy J Clin Med 9 2885-undefined

[34] Culp MBB(2020)Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European cardio-oncology guidelines J Am Heart Assoc 9 18403-undefined

[35] Soerjomataram I(2021)Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association Circ Genomic Precis Med 14 E000082-undefined

[36] Efstathiou JA(2014)Do physicians’ financial incentives affect medical treatment and patient health? Am Econ Rev 104 1320-undefined

[37] Bray F(2010)Translating monetary inputs into health care provision: a comparative analysis of the impact of different modes of public policy J Comp Policy Anal Res Pract 12 11-undefined

[38] Jemal A(2019)Time trend and characteristics of prostate cancer diagnosed in Hong Kong (China) in the past two decades Asian J Androl 21 104-undefined

[39] Guo Y(2016)Cardiovascular outcomes associated with use of clarithromycin: population based study BMJ. 352 h6926-undefined

[40] Dong X(2017)Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation J Am Med Assoc. 317 1151-undefined

[31] Addolorato G(2014)ABCDE steps to prevent heart disease in breast cancer survivors Circulation. 130 e157-undefined

[32] Ammirati E(2016)Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer Circulation. 133 537-undefined

[33] Baddour LM(2020)Management of cardiac toxicity induced by chemotherapy J Clin Med 9 2885-undefined

[34] Culp MBB(2020)Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European cardio-oncology guidelines J Am Heart Assoc 9 18403-undefined

[35] Soerjomataram I(2021)Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association Circ Genomic Precis Med 14 E000082-undefined

[36] Efstathiou JA(2014)Do physicians’ financial incentives affect medical treatment and patient health? Am Econ Rev 104 1320-undefined

[37] Bray F(2010)Translating monetary inputs into health care provision: a comparative analysis of the impact of different modes of public policy J Comp Policy Anal Res Pract 12 11-undefined

[38] Jemal A(2019)Time trend and characteristics of prostate cancer diagnosed in Hong Kong (China) in the past two decades Asian J Androl 21 104-undefined

[39] Guo Y(2016)Cardiovascular outcomes associated with use of clarithromycin: population based study BMJ. 352 h6926-undefined

[40] Dong X(2017)Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation J Am Med Assoc. 317 1151-undefined